MAtrix Therapy for Hard-to-heal ChrOnic Wounds (MATHCOW)

  • days left to enroll
  • participants needed
  • sponsor
    Organ, Tissue, Regeneration, Repair and Replacement
Updated on 7 March 2022


CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds.

This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.


§ Study context:

CACIPLIQ20® is a bioengineered structural analogue of heparan sulfate glycosaminoglycans. Numerous experimental studies have provided strong evidence that CACIPLIQ20® promotes tissue regeneration by reconstructing the cellular microenvironment following tissue injury. Case studies collected in various clinical settings support the clinical interest of CACIPLIQ20® in the management of hard-to-heal chronic wounds.

CACIPLIQ20® is currently a class III CE marked medical device (NSAI-0050 CE MARK ECDEC-NL-A4) with the following indications:

Chronic ulcers showing no tendency to heal after 6 months of standard care, or still unhealed after 12 months, such as:

  • Pressure ulcers;
  • Peripheral arterial disease (such as Stage IV Leriche & Fontaine) ulcers;
  • Diabetic ulcers (including amputation).

CACIPLIQ20® is available in various European and non-European countries and currently primarily used in managing hard-to-heal wounds.

Therefore, there is an opportunity to organize a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use and to collect data that may help to highlight its efficacy and safety and estimate its cost-effectiveness.

§ Hard-to-heal leg/foot ulcerations:

Leg ulcers of venous, mixed or arterial origin as well as neuropathic or neuroischaemic diabetic foot ulcers represent the most prevalent chronic wounds followed and managed in daily practices.

Arterial leg ulcers and Diabetic foot ulcers (DFU)s (especially for neuroischaemic DFUs) have frequently a rather poor healing prognosis despite revascularization attempts and application of best local cares including, for DFUs, wearing of appropriate off-loading devices. The risk of deciding minor or major lower limb amputation is high and the chance to obtain wound closure at 20-24 weeks is, at the best, around 20-30%.

For leg ulcers of venous origin (ankle brachial pressure index (ABPI) ≥0.8) or of mixed origin (ABPI ranges between 0.6 and 0.8), the healing prognosis is better with application of best local cares and the use when the ABPI is >0.7 or 0.8 of an efficient venous bandaging. Nevertheless, when initiating the management of large old wounds (area >10 cm² and ulcer present for at least 6 months) the chance to obtain wound closure at 20-24 weeks is of 20-30% at best.

This survey will specifically include patients presenting a hard-to-heal foot/leg ulceration such as: leg ulcers of predominantly venous origin but with an ulcer surface >10 cm² and/or an estimated wound duration of at least 5 months, leg ulcer with arterial participation including critical limb ischemia, or neuropathic and neuroischaemic DFUs.

§ Study organization:

The inclusion of patients is decided the day when the addition of CACIPLIQ20® to the standard of local care is decided. The follow-up of the patient in the cohort will be carried out until the target wound is closed or up to a maximum of 20 weeks.

The inclusion and follow-up of patients are ensured, in agreement and in cooperation with the healthcare team of the subject, by doctors and expert nurses from the Cicat Occitanie network. This network relies on secured and validated teleconsultation tools. The inclusion of a patient in the cohort will not change the usual functioning of the network.

Condition Chronic Ulcer of Leg or Foot, Diabetic Foot Ulcer, Arterial Ulcer, Venous Ulcer of Leg
Treatment CACIPLIQ20®
Clinical Study IdentifierNCT05170984
SponsorOrgan, Tissue, Regeneration, Repair and Replacement
Last Modified on7 March 2022


Yes No Not Sure

Inclusion Criteria

Patients justifying a treatment with CACIPLIQ20® according to a care provider
Patients presenting with a chronic wound that has not shown signs of improvement following treatment for at least 6 months prior to inclusion into the study
Adult patients of either gender aged at least 18 and without upper limit for age
Patients having received a full written and oral information about study conduct and objectives and having given a written consent to participate according to local regulations
Patients being seen as outpatients and for whom no hospitalization is expected/planned in the 6 forthcoming weeks
Patients who can and are willing to be followed by a study investigator for the duration of the study
Patients benefiting from a valid health insurance or social security coverage
Target Wound Inclusion Criteria
Current wound that has not been previously treated with CACIPLIQ20®
Target wound located below the knee
Target wound is either
a leg ulceration predominantly of venous origin (no ischemia as previously defined) with an area >10 cm² and/or a duration of at least 5 months
a leg ulceration of any size or duration, with a documented ischemic lower limb problem
a foot ulceration of any size or duration, documented as a diabetic foot ulceration (DFU)
If more than one wound is present and eligible, investigators will be required to
select one as the target wound for this study. This wound should be the
largest one. If wounds are of similar size, the ulceration considered by the
investigator as the worst will be selected

Exclusion Criteria

Female patients who are pregnant, or lactating
Bedridden patients unable to spend at least one hour per day sitting in a chair
Patients suffering from severe cognitive problems precluding any voluntary participation to the study
Patients with, according to investigator's opinion, a very poor life expectancy
Patients with leg or foot ulcerations which are not of venous, arterial or diabetic origin (e.g. Martell's ulcer and related ulcers, pressure ulcers, traumatic wounds or burns)
Patients whose target wound is located on an amputation stump
Patients presenting with a fungating wound at the time of inclusion
Patients in an emergency situation and unable to give consent
Patients intolerant to one of the study device components or to heparinoids
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note